As women navigate the physiological shifts of perimenopause, many seek information about various supplements. Inositol, specifically myo-inositol and D-chiro-inositol, is one such compound that frequently comes up in discussions related to hormonal balance and metabolic well-being during this life stage.
Understanding the long-term safety profile of any supplement is crucial, especially when considering consistent use. This article aims to provide an evidence-based overview of what current research suggests regarding the sustained use of inositol, focusing on information relevant to perimenopausal women.
Understanding Inositol: Myo-Inositol and D-Chiro-Inositol
Inositol is a carbocyclic sugar that plays a role in various cellular processes. While there are nine possible stereoisomers, myo-inositol is the most abundant form found in nature and in the human body. D-chiro-inositol is another stereoisomer that has also garnered significant interest, particularly in discussions related to insulin signaling [1].
These forms of inositol act as secondary messengers in several signaling pathways, influencing cellular responses to hormones like insulin and follicle-stimulating hormone. Their involvement in these pathways is why they are often discussed in contexts related to metabolic health and reproductive well-being [1].
General Safety Profile of Inositol Supplementation
Research exploring the pharmacodynamics and pharmacokinetics of inositol suggests that it is generally well-tolerated at typical supplemental doses [1]. The most directly relevant human data for women in midlife come from randomised trials in postmenopausal women with metabolic syndrome, in which myo-inositol was given at 2 g twice daily alongside a low-energy diet for six months [2], and, in a second trial using the same dose, for a full twelve months [3].
The body naturally produces inositol, and it is also present in many foods. This intrinsic presence and dietary intake contribute to its generally favorable safety profile. Adverse effects, when reported, are often mild and typically associated with higher doses, such as gastrointestinal discomfort. Sustained dosing has been studied most directly in postmenopausal rather than perimenopausal women: the twelve-month trial above followed 80 women taking 2 g twice daily through to its endpoint [3], and a separate six-month randomised placebo-controlled trial enrolled 155 postmenopausal women on inositol combined with alpha lipoic acid [4].
Considerations for Perimenopausal Women
Perimenopause is a period marked by fluctuating hormone levels, which can influence various bodily systems. It is worth being exact about who these trials recruited: they enrolled postmenopausal women, not women still cycling irregularly, so the evidence covering the perimenopausal transition itself remains thinner than the evidence covering the years after it. A review of inositols in midlife draws the same line, resting its conclusions on randomised data gathered in postmenopausal women [5]. The involvement of inositol in insulin signaling and cellular communication could be relevant during a time when metabolic changes may occur [1].
Symptom-level outcomes have been recorded in this population too. In a retrospective study of 200 menopausal women with metabolic syndrome taking a daily sachet containing 2,000 mg of myo-inositol with cocoa polyphenols and soy isoflavones, the share reporting four to nine hot flushes fell from 54% to 18% over six months, and body mass index and waist circumference improved [6]. That study was retrospective and the sachet combined three ingredients, so it cannot attribute the change to inositol alone. What it does establish is that six months of use in menopausal women has been observed and written up, rather than left unexamined.
Potential Side Effects and Interactions
Based on general research, inositol is often associated with a low incidence of adverse effects. When they do occur, they are typically mild and transient, such as nausea, gas, or diarrhea, usually at higher doses [1]. It is worth being precise about what the midlife trials do and do not tell you. They were built around metabolic endpoints such as insulin resistance, lipids and blood pressure, and they report those outcomes rather than a formal tally of adverse events [2][3]. Their value on a safety page is that women took 2 g twice daily for six and twelve months under trial conditions, not that they set out to measure harm.
Regarding interactions, the most directly relevant observation in this population involves metformin. In a prospective observational study, postmenopausal women with prediabetes who had already been taking myo-inositol for at least six months responded more strongly to metformin, on glucose, insulin resistance and glycated haemoglobin, than matched women who were not taking inositol [7]. That is an additive metabolic effect rather than a harmful one, but it is a concrete reason to tell your prescriber you take inositol if you also take metformin, because it can change how much work the medication appears to be doing.
Absence of Evidence vs. Evidence of Absence
It is crucial to distinguish between ‘absence of evidence’ and ‘evidence of absence’ when discussing long-term safety. For inositol in midlife the honest position is narrower than either. Randomised follow-up runs to twelve months in postmenopausal women [3], so continuous use beyond about a year has not been trialled in this group, and the perimenopausal transition itself has been studied less than the years that follow it. Neither of those is a finding of harm, and neither is a clean bill of health.
The existing literature, while not exclusively focused on the perimenopausal years, suggests a generally favorable safety profile for inositol at typical supplemental dosages. One caveat belongs on a page about long-term use, and it concerns dose rather than duration. Most midlife supplementation uses myo-inositol, or a 40:1 myo to D-chiro blend. D-chiro-inositol taken alone at high doses behaves differently: in young adult female mice given a human-equivalent of roughly 1,200 mg per day for 21 days, ovarian histology was altered, serum testosterone rose and ovarian aromatase fell, while higher equivalents produced ovarian lesions resembling those of aged mice [8]. That is an animal study and does not transfer directly to women. It is, though, the clearest published reason to stay with the studied myo-inositol doses and the standard 40:1 ratio rather than escalating D-chiro-inositol on your own.
References
- Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert opinion on drug metabolism & toxicology, 2016
- Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause (New York, N.Y.), 2011
- One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric : the journal of the International Menopause Society, 2012
- Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials, 2013
- Inositols in Midlife. Journal of mid-life health, 2018
- Dietary Supplementation of Myo-Inositol, Cocoa Polyphenols, and Soy Isoflavones Improves Vasomotor Symptoms and Metabolic Profile in Menopausal Women with Metabolic Syndrome: A Retrospective Clinical Study. Medicina (Kaunas, Lithuania), 2024
- Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women. Gynecologic and obstetric investigation, 2022
- High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. International journal of molecular sciences, 2021
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
